ARMISTICE CAPITAL, LLC
CIK 1601086 · last filed 2023-06-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$228.37M
Companies
15
Total Filings
83
Lifetime Open-Market Net
$140.94M
Filer Profile
Reported Address
510 MADISON AVENUE, 7TH FLOORNEW YORK, NY 10022
Phone
(212) 231-4932
State of Incorporation
DE
Related Filers
Steven Boyd — 239 joint filings, latest 2023-06-28
Armistice Capital Master Fund Ltd. — 233 joint filings, latest 2023-06-28
Cerecor Inc. — 108 joint filings, latest 2023-06-28
LM FUNDING AMERICA, INC. — 8 joint filings, latest 2026-08-14
IRONWOOD PHARMACEUTICALS INC — 7 joint filings, latest 2026-08-14
SPECTRUM PHARMACEUTICALS INC — 7 joint filings, latest 2023-02-14
Citius Pharmaceuticals, Inc. — 5 joint filings, latest 2022-02-15
CYTRX CORP — 3 joint filings, latest 2024-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AVTX | Director | 3,191 | $16.12 | $51.4K | -$1.94M | 6 | 2023-06-28 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Director | 39,662,442 | $2.93 | $116.21M | $51.07M | 15 | 2021-08-06 |
| Vyome Holdings, Inc (RSLS) Delisted | 10%+ Owner | 48 | $15.68 | $753 | $0 | 1 | 2021-06-29 |
| EYEG | Director | 6,693,202 | $33.99 | $227.47M | $36.97M | 10 | 2021-01-08 |
| AYTU | Director | 133,334 | $1.99 | $265.3K | $24.00M | 1 | 2020-12-15 |
| TENX | Director | 2,519 | $1.86 | $4.7K | $277.6K | 2 | 2020-09-09 |
| Vaxart, Inc. (VXRT) Delisted | Director | 16,800,000 | $0.32 | $5.38M | -$1.57M | 1 | 2020-05-29 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | 10%+ Owner | 4,468,000 | — | — | $1.25M | 2 | 2020-03-18 |
| Traws Pharma, Inc. (ONTXW) Delisted | 10%+ Owner | 1,633,404 | $0.07 | $109.6K | -$39.0K | 1 | 2019-09-25 |
| ACHV | 10%+ Owner | 81,909 | $7.06 | $578.3K | -$404.5K | 1 | 2019-06-13 |
| Del Frisco's Restaurant Group, Inc. (DFRG) Delisted | 10%+ Owner | 6,525,000 | — | — | $29.99M | 11 | 2019-06-06 |
| Valeritas Holdings Inc. (VLRX) Delisted | 10%+ Owner | 2,116,000 | — | — | $465.8K | 4 | 2019-05-28 |
| CASSAVA SCIENCES INC (PTIE) Delisted | 10%+ Owner | 1,651,340 | — | — | -$2.02M | 1 | 2018-10-05 |
| Fresh Tracks Therapeutics, Inc. (VICL) Delisted | 10%+ Owner | 862,146 | — | — | $69.2K | 1 | 2018-06-22 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Director | 32,440,000 | — | — | $2.82M | 8 | 2018-04-23 |
Recent Filings · Page 2 of 9
83 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-08 | EYEG | Buy (P) | +4,593,303 | $24.00M | EDGAR |
| 2020-12-15 | AYTU | Buy (P) | +4,000,002 | $24.00M | EDGAR |
| 2020-12-04 | — | Buy (P) | +19,200 | $79.8K | |
| 2020-11-17 | — | Buy (P) | +2,931 | $12.3K | |
| 2020-09-28 | — | Sell (S) | −129,669 | -$16.9K | |
| 2020-09-25 | — | Buy (P) | +6,000 | $24.4K | |
| 2020-09-23 | — | Sell (S) | −501,000 | -$73.7K | |
| 2020-09-16 | — | Sell (S) | −1,011,252 | -$165.7K | |
| 2020-09-09 | TENX | Buy (P) | +96,000 | $136.6K | EDGAR |
| 2020-09-09 | Avalo Therapeutics, Inc. (CERC) Delisted | Buy (P) | +300,000 | $660.0K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.